Search

Author/Creator Shilkrut, Mark

1. Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704). (6th November 2014)

Authors:
Andtbacka, Robert HI; Collichio, Frances A; Amatruda, Thomas; Senzer, Neil; Chesney, Jason; Delman, Keith; Spitler, Lynn; Puzanov, Igor; Agarwala, Sanjiv; Milhem, Mohammed; Harrington, Kevin; Middleton, Mark; Li, Ai; Shilkrut, Mark; Coffin, Robert; Kaufman, Howard
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 2(2014)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial. (6th November 2014)

Authors:
Kaufman, Howard L; Andtbacka, Robert HI; Collichio, Frances A; Wolf, Michael; Li, Ai; Shilkrut, Mark; Puzanov, Igor; Ross, Merrick
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 2(2014)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms. Issue 3 (March 2021)

Authors:
Yao, James C; Strosberg, Jonathan; Fazio, Nicola; Pavel, Marianne E; Bergsland, Emily; Ruszniewski, Philippe; Halperin, Daniel M; Li, Daneng; Tafuto, Salvatore; Raj, Nitya; Campana, Davide; Hijioka, Susumu; Raderer, Markus; Guimbaud, Rosine; Gajate, Pablo; Pusceddu, Sara; Reising, Albert; Degtyar...
Journal:
Endocrine-related cancer
Issue:
Volume 28:Issue 3(2021)
Page Start:
161
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Issue 12 (13th July 2016)

Authors:
Andtbacka, Robert H. I.; Agarwala, Sanjiv S.; Ollila, David W.; Hallmeyer, Sigrun; Milhem, Mohammed; Amatruda, Thomas; Nemunaitis, John J.; Harrington, Kevin J.; Chen, Lisa; Shilkrut, Mark; Ross, Merrick; Kaufman, Howard L.
Journal:
Head & neck
Issue:
Volume 38:Issue 12(2016)
Page Start:
1752
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Phase I Trial of Dose-escalated Whole Liver Irradiation With Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients With Neuroendocrine Hepatic Metastases. (April 2018)

Authors:
Shilkrut, Mark; Sapir, Eli; Hanasoge, Sheela; Schipper, Matthew J.; Normolle, Daniel P.; Ben-Josef, Edgar; Ensminger, William; Lawrence, Theodore S.; Feng, Mary
Journal:
American journal of clinical oncology
Issue:
Volume 41:Number 4(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. The addition of low‐dose‐rate brachytherapy and androgen‐deprivation therapy decreases biochemical failure and prostate cancer death compared with dose‐escalated external‐beam radiation therapy for high‐risk prostate cancer1. Issue 3 (14th August 2012)

Authors:
Shilkrut, Mark; Merrick, Gregory S.; McLaughlin, P. William; Stenmark, Matthew H.; Abu‐Isa, Eyad; Vance, Sean M.; Sandler, Howard M.; Feng, Felix Y.; Hamstra, Daniel A.
Journal:
Cancer
Issue:
Volume 119:Issue 3(2013)
Page Start:
681
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗